Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03611686

Acronym

OPALE

Enrollment

219

Registered

2018-08-02

Start date

2018-04-17

Completion date

2026-04-30

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Prostate Adenocarcinoma

Brief summary

Evaluation the overall survival of patients with metastatic prostate adenocarcinoma resistant to castration

Interventions

DRUGLocal chemotherapy

Local chemotherapy will be administrated according to local recommendation

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient monitored for castration-resistant metastatic prostate * Patients starting a first or second line treatment as part of castration resistance * Patient not objecting to the study after reading the information letter * Patient aged over 18 years

Exclusion criteria

* Patient monitored for non-metastatic prostate cancer * Patient monitored for castration-nonresistant prostate cancer * Patient not able to understand the information letter

Design outcomes

Primary

Measure	Time frame
Number of alive patient	3 years

Secondary

Measure	Time frame
Number of alive patient disease free	3 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026